Literature DB >> 28797648

Overview of transcriptomic analysis of all human proteases, non-proteolytic homologs and inhibitors: Organ, tissue and ovarian cancer cell line expression profiling of the human protease degradome by the CLIP-CHIP™ DNA microarray.

Reinhild Kappelhoff1, Xose S Puente2, Claire H Wilson1, Arun Seth3, Carlos López-Otín2, Christopher M Overall4.   

Abstract

The protease degradome is defined as the complete repertoire of proteases and inhibitors, and their nonfunctional homologs present in a cell, tissue or organism at any given time. We review the tissue distribution of virtually the entire degradome in 23 different human tissues and 6 ovarian cancer cell lines. To do so, we developed the CLIP-CHIP™, a custom microarray based on a 70-mer oligonucleotide platform, to specifically profile the transcripts of the entire repertoire of 473 active human proteases, 156 protease inhibitors and 92 non-proteolytically active homologs known at the design date using one specific 70-mer oligonucleotide per transcript. Using the CLIP-CHIP™ we mapped the expression profile of proteases and their inhibitors in 23 different human tissues and 6 ovarian cancer cell lines in 104 sample datasets. Hierarchical cluster analysis showed that expression profiles clustered according to their anatomic locations, cellular composition, physiologic functions, and the germ layer from which they are derived. The human ovarian cancer cell lines cluster according to malignant grade. 110 proteases and 42 inhibitors were tissue specific (1 to 3 tissues). Of these 110 proteases 69% (74) are mainly extracellular, 30% (34) intracellular and 1% intramembrane. Notably, 35% (197/565) of human proteases and 30% (47/156) of inhibitors were ubiquitously expressed in all 23 tissues; 27% (155) of proteases and 21% (32) of inhibitors were broadly expressed in 4-20 tissues. Our datasets provide a valuable resource for the community of baseline protease and inhibitor relative expression in normal human tissues and can be used for comparison with diseased tissue, e.g. ovarian cancer, to decipher pathogenesis, and to aid drug development. This article is part of a Special Issue entitled: Proteolysis as a Regulatory Event in Pathophysiology edited by Stefan Rose-John. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CLIP-CHIP; Degradome; Inactive-homologues; Microarray; Ovarian cancer; Protease and inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28797648     DOI: 10.1016/j.bbamcr.2017.08.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  11 in total

1.  Twenty years of bioinformatics research for protease-specific substrate and cleavage site prediction: a comprehensive revisit and benchmarking of existing methods.

Authors:  Fuyi Li; Yanan Wang; Chen Li; Tatiana T Marquez-Lago; André Leier; Neil D Rawlings; Gholamreza Haffari; Jerico Revote; Tatsuya Akutsu; Kuo-Chen Chou; Anthony W Purcell; Robert N Pike; Geoffrey I Webb; A Ian Smith; Trevor Lithgow; Roger J Daly; James C Whisstock; Jiangning Song
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 2.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

3.  C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease.

Authors:  Antoine Dufour; Caroline L Bellac; Ulrich Eckhard; Nestor Solis; Theo Klein; Reinhild Kappelhoff; Nikolaus Fortelny; Parker Jobin; Jacob Rozmus; Jennifer Mark; Paul Pavlidis; Vincent Dive; Sean J Barbour; Christopher M Overall
Journal:  Nat Commun       Date:  2018-06-20       Impact factor: 14.919

Review 4.  Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.

Authors:  Jeremy S Frieling; Conor C Lynch
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

5.  Persistent Salmonella enterica Serovar Typhimurium Infection Induces Protease Expression During Intestinal Fibrosis.

Authors:  Katrin Ehrhardt; Natalie Steck; Reinhild Kappelhoff; Stephanie Stein; Florian Rieder; Ilyssa O Gordon; Erin C Boyle; Peter Braubach; Christopher M Overall; B Brett Finlay; Guntram A Grassl
Journal:  Inflamm Bowel Dis       Date:  2019-09-18       Impact factor: 5.325

6.  Purification and Biochemical Characterization of a New Protease Inhibitor from Conyza dioscoridis with Antimicrobial, Antifungal and Cytotoxic Effects.

Authors:  Aida Karray; Mona Alonazi; Slim Smaoui; Philippe Michaud; Dina Soliman; Abir Ben Bacha
Journal:  Molecules       Date:  2020-11-20       Impact factor: 4.411

7.  Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy.

Authors:  Magdalena Rudzińska; Cenk Daglioglu; Lyudmila V Savvateeva; Fatma Necmiye Kaci; Rodolphe Antoine; Andrey A Zamyatnin
Journal:  Drug Des Devel Ther       Date:  2021-01-06       Impact factor: 4.162

Review 8.  Endothelial Cells in Emerging Viral Infections.

Authors:  Johanna Hol Fosse; Guttorm Haraldsen; Knut Falk; Reidunn Edelmann
Journal:  Front Cardiovasc Med       Date:  2021-02-24

Review 9.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

Review 10.  KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?

Authors:  Hannu Koistinen; Jaana Künnapuu; Michael Jeltsch
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.